IASLC World Conference on Lung Cancer | Conference

Dr. Camidge on the ALTA Study of Brigatinib in NSCLC

October 16th 2017

D. Ross Camidge, MD, PhD, a professor of medical oncology at the University of Colorado, discusses the results of the ALTA trial, which is exploring brigatinib (Alunbrig) in patients with ALK-positive non-small cell lung cancer.

Lower Dose Ceritinib With Food as Effective But Better Tolerated for ALK+ NSCLC

October 16th 2017

A lower dose of ceritinib taken with a low-fat meal showed similar efficacy with fewer dose reductions and less severe gastrointestinal adverse events versus a 750-mg dose taken without food for patients with untreated ALK-positive metastatic non–small cell lung cancer.

Nivolumab/Ipilimumab Combo Active in SCLC With High Tumor Burden

October 16th 2017

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) induced an objective response rate of 46% in patients with recurrent small cell lung cancer with high tumor mutation burden, according to an exploratory analysis from the phase I/II CheckMate-032 study.

FISHing for a Better Assay in ALK-Positive Lung Cancer

October 16th 2017

In addition to proving the superiority of alectinib versus crizotinib, the phase III ALEX trial provided clear guidance on which of 2 assays evaluated could provide stronger guidance on which patients would respond to ALK-specific therapy.

IASLC Conference Will Highlight PACIFIC Trial QoL Data on Durvalumab

October 14th 2017

Fred R. Hirsch, MD, PhD, provides highlights of the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer, leading with his excitement for updated quality-of-life data from the PACIFIC trial of patients with locally advanced, unresectable stage III non–small cell lung cancer.

Avelumab Shows Promise as Frontline Immunotherapy Alternative in NSCLC

January 11th 2017

Immunotherapy is quickly becoming a mainstay in the frontline setting for the treatment of patients with metastatic non–small cell lung cancer.

Dr. Carbone on Effectiveness of Different Lung Cancer Therapies

January 4th 2017

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.

Nivolumab Shows Promise in Mesothelioma

December 14th 2016

Treatment with the PD-1 inhibitor nivolumab showed promising results in patients with recurrent malignant pleural mesothelioma.

First Steps Taken Toward Harmonization of PD-L1 Immunohistochemistry Testing in France

December 8th 2016

Determination of the PD-L1 status of a patient’s tumor has become increasingly important for informing the clinical decision whether to offer certain immunotherapeutic agents, making standardization of the tests and antibodies used to determine the PD-L1 status necessary to provide accurate and consistent results.

Durvalumab Provides Durable Response in Heavily Pretreated Metastatic NSCLC

December 8th 2016

Durvalumab treatment in the second-line setting or beyond demonstrated clinical benefit and led to durable responses in heavily pretreated patients with locally advanced or metastatic non-small cell lung cancer.

Atezolizumab Improves Survival in Second-Line NSCLC

December 8th 2016

Treatment with the PD-L1 inhibitor atezolizumab significantly improved overall survival compared to standard chemotherapy in patients with non–small lung cancer who progressed on platinum-based chemotherapy.

Frontline Pembrolizumab Shows Superior Health-Related QoL in NSCLC

December 7th 2016

Patients with non–small cell lung cancer treated in the pembrolizumab arm of the KEYNOTE-024 trial experienced improved quality of life compared with patients who were treated with standard chemotherapy.

Dr. Wakelee on Detection of EGFR T790M Mutation in NSCLC

December 7th 2016

Heather Wakelee, MD, medical oncologist, Stanford University Medical Center, discusses a next-generation sequencing platform for the detection of non-small cell lung cancer (NSCLC) EGFR T790M mutation in urine and plasma samples, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Ramalingam on the Role of Osimertinib in EGFR T790M-Positive Advanced NSCLC

December 7th 2016

Suresh S. Ramalingam, MD, professor, Department of Hematology and Medical Oncology, Deputy Director, Winship Cancer Institute of Emory University, discusses the role of osimertinib in the treatment of patients with EGFR T790M-positive advanced non-small cell lung cancer, during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Osimertinib Beats Chemo in Second-Line T790M-Mutant NSCLC

December 7th 2016

Osimertinib (Tagrisso) reduced the risk of disease progression by 70% compared with a chemotherapy doublet in patients with EGFR T790M-mutant non–small cell lung cancer (NSCLC) who progressed after first-line targeted therapy.

Frontline Ceritinib Improves PFS Over Platinum-Based Chemo in ALK+ NSCLC

December 7th 2016

Frontline treatment with ceritinib (Zykadia) improved progression-free survival over standard chemotherapy in patients with ALK-rearranged non–small cell lung cancer.

Dr. Juergens on the IND.226 Trial in Advanced Non-Squamous NSCLC

December 6th 2016

Rosalyn Juergens, MD, PhD, assistant professor, Department of Oncology, Division of Medical Oncology, McMaster University, discusses the results of the IND.226 trial, in an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Dr. Verschraegen on the JAVELIN Solid Tumor Trial in Advanced NSCLC

December 6th 2016

Claire Verschraegen, MD, professor of Medical Oncology, University of Vermont Cancer Center, discusses the results of the JAVELIN Solid Tumor trial during an interview at the IASLC 17th World Conference on Lung Cancer in Vienna, Austria.

Icotinib Improves Intracranial PFS in EGFR-Mutant NSCLC and Brain Mets

December 6th 2016

Treatment with icotinib more than doubled intracranial progression-free survival compared with whole brain irradiation combined with standard chemotherapy.

Improved PFS, ORR With Frontline Nivolumab and Nivolumab/Ipilimumab Combo in NSCLC

December 6th 2016

Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.